JPRN-jRCT2071220019已完成1 期
The Phase I Single Dose Study of OP-2024 in Healthy Male Volunteers
Taguchi Fumi0 个研究点目标入组 24 人开始时间: 2022年6月29日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 40age old（—）
- 性别
- Male
入选标准
- •1) Healthy Japanese male.
- •2) Those with age >= 18 to <= 40 years.
- •3) Those with BMI >= 18.5 to < 25.0.
- •4) Those who have provided voluntary written consent to participate in the study.
排除标准
- •1) Those with a history of allergies to investigational drug ingredients, drugs, or foods
- •2) Those who are undergoing treatment for, or have a history of, respiratory, circulatory, central nervous system, gastrointestinal, hepatic, renal, hematopoietic, or endocrine disorders that affect pharmacokinetics
- •3) Other protocol defined exclusion criteria could apply
研究者
相似试验
招募中
1 期
To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Caucasian and Ethnic Chinese PopulationsACTRN12621000848808EQRx, Inc30
已完成
1 期
A study in healthy volunteers to investigate how the test medicine CORT113176 is taken up by the body when given with food and without foodAmyotrophic lateral sclerosis (ALS)Nervous System DiseasesMotor neuron diseaseISRCTN52169163Corcept Therapeutics (United States)35
Enrolling By Invitation
1 期
Engineered T cells for the treatment of B-cell leukemiaB-cell leukemiaCAR-CD19 T cellTCTR20160921001TCELS15
已完成
1 期
A Single Microdose Study to Evaluate the Pharmacokinetics of INS018_055 in Healthy ParticipantsACTRN12621001541897Insilico Medicine Hong Kong Limited8
撤回
1 期
A Phase 1 Single Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EARLI-001ACTRN12622001571763Earli Pty. Ltd.10